Web Analytics

3 Latest Announced Rounds

  • $67,000,000
    Series A
    Biotechnology Research
    Apr 2nd, 2025
  • $10,000,000
    Seed

    2 Investors

    Software Development
    Apr 2nd, 2025
  • $5,200,000
    Series A

    3 Investors

    Technology, Information and Internet
    Apr 2nd, 2025
$1,676.17M Raised in 53 Funding Rounds in the past 7 Days - View All

Funding Round Profile

RheumaGen

start up
United States - Denver, Colorado
  • 10/01/2025
  • Series A
  • $15,000,000

RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.


Related People

Richard FreedFounder

Richard Freed United States - Denver, Colorado

Co-Founder, CEO, Husband, Dad